Results 31 to 40 of about 24,787 (310)

Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine [PDF]

, 2019
Background: The development of therapeutic vaccines requires thorough knowledge of potential hazards associated with long-term inactivation of self-proteins.
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis

Journal of Allergy and Clinical Immunology: Global
Background: Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials.
Jayant M. Pinto, MD, Mirko Fillbrunn, PhD, Bruno Martins, PhD, Min Yang, PhD, Chao Chen, PhD, Scott Nash, MD, Mark Corbett, MD, Aakash Gandhi, PhD, Zhixiao Wang, PhD   +8 more
doaj   +1 more source

Atopic eczema [PDF]

, 2016
Atopic eczema is an itchy inflammatory skin disease with a chronic relapsing–remitting course; it has increased in prevalence in recent decades and now affects up to 25% of school-aged children in the developed world and up to 10% of adults.
Deckert, Flohr, Kelleher, Madhok, Nankervis, Rodriguez, Simpson, Williams   +7 more
core   +2 more sources

Cicatricial ectropion in a patient treated with dupilumab

American Journal of Ophthalmology Case Reports, 2017
Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two ...
Alexander C. Barnes, Alexander D. Blandford, Julian D. Perry   +2 more
doaj   +1 more source

Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis. [PDF]

, 2019
Chronic itch remains a highly prevalent disorder with limited treatment options. Most chronic itch diseases are thought to be driven by both the nervous and immune systems, but the fundamental molecular and cellular interactions that trigger the ...
Barton, Gregory M, Bautista, Diana M, Brem, Rachel B, Brock, Emily C, Deguine, Jacques, Gronert, Karsten, Hill, Rose Z, Kucirek, Natalie, Rifi, Ziad, Schwendinger-Schreck, Jamie, Walsh, Carolyn M, Wei, Jessica   +11 more
core   +1 more source

Tumors in the setting of dupilumab use: A review of the literature

World Allergy Organization Journal
Dupilumab is the first monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) and has significantly improved the quality of life of AD patients.
Shumeng Guo, Liangchun Wang, MD, PhD, Dingfang Bu, MD, PhD, Fengjie Liu, MD, PhD   +3 more
doaj   +1 more source

Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report

SAGE Open Medical Case Reports, 2020
A 36-year-old Caucasian female with a long history of atopic dermatitis presented with multiple flares eventually leading to dupilumab therapy. Five months into the dupilumab therapy, she presented with well-demarcated erythematous plaques with silvery ...
Ho Seung Kim, Jensen Yeung
doaj   +1 more source

How Can Dupilumab Cause Eosinophilic Pneumonia?

Biomolecules, 2022
Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are limited in previous studies. Herein, we report two cases in which EP developed subsequent to the administration of dupilumab for eosinophilic chronic rhinosinusitis ...
Momoko Kurihara, Katsunori Masaki, Emiko Matsuyama, Masato Fujioka, Reina Hayashi, Saki Tomiyasu, Kotaro Sasahara, Keeya Sunata, Masato Asaoka, Yuto Akiyama, Miyuki Nishie, Misato Irie, Takae Tanosaki, Hiroki Kabata, Koichi Fukunaga   +14 more
doaj   +1 more source

Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]

, 2017
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe, Brusselle, Guy, de Haard, Hans, Godar, Marie, Lambrecht, Bart   +4 more
core   +3 more sources

Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Arrhythmias affect approximately half of patients with Costello syndrome (CS, OMIM # 218040), with non‐reentrant atrial tachycardia being the most common. This case describes an infant with Costello syndrome carrying the pathogenic HRAS c.34G>A (p.G12S) variant who developed early‐onset, drug‐refractory multifocal atrial tachycardia (MAT ...
Vanina Taliercio, Annabelle Wilcox, Stacey Cole, Josue Flores Daboub, José E. Morales Moreno, Kasey G. Andrews, S. Yukiko Asaki, Thomas A. Pilcher, Martin Tristani‐Firouzi, Mary C. Niu, David Viskochil, Benjamin Hammond   +11 more
wiley   +1 more source